7 January 2009 -- SkyePharma PLC today announces that its partner Nitec has received the Final Assessment Report from the German BfArM, concluding that Lodotra is approvable for the treatment of rheumatoid arthritis and associated morning stiffness, in 15 European countries, including Germany as the Reference Member State, under the EMEA’s Decentralised Procedure.
The details can be read here.
No comments:
Post a Comment